CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 199 enrolled
Drug / intervention
GWP42003-P +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02224703
NCT02224703Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.

Jazz Pharmaceuticals·interventional·Posted Aug 25, 2014·Updated Sep 28, 2022

In Brief

A Phase 3 clinical trial evaluating GWP42003-P and Placebo Control for Epilepsy and Dravet Syndrome. Completed, enrolled 199 participants across 38 sites in 6 countries.

Detailed Summary

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Dravet Syndrome
CountriesAustralia, Israel, Netherlands, Poland, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 25, 2014
Enrollment StartApr 13, 2015
Primary CompletionApr 9, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.9 years ago

Interventions

GWP42003-Pdrug

Placebo Controldrug